Michael Hayden's most recent trade in Ionis Pharmaceuticals Inc was a trade of 4,079 Common Stock done . Disclosure was reported to the exchange on July 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 4,079 | 54,298 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2025 | 4,079 | 9,897 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 11,518 | 11,518 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2025 | 5,220 | 13,976 | - | - | Restricted Stock Unit | |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 238,864 | 899,843 | - | - | Share option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 31.86 per share. | 01 May 2025 | 15,000 | 50,219 (0%) | 0% | 31.9 | 477,900 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 56,400 | 56,400 | - | - | Stock Option (Right to Buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 36.23 per share. | 23 Dec 2024 | 2,500 | 35,219 (0%) | 0% | 36.2 | 90,583 | Common Stock |
| Ionis Pharma Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 36.20 per share. | 23 Dec 2024 | 2,500 | 32,719 (0%) | 0% | 36.2 | 90,496 | Common Stock |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 10,111 | 10,111 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 4,079 | 8,756 | - | - | Restricted Stock Unit | |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 163,934 | 660,979 | - | - | Share option (right to buy) | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 45,150 | 45,150 | - | - | Stock Option (Right to Buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 5.90 per share. | 08 Aug 2023 | 30,000 | 1,303,397 | - | 5.9 | 177,000 | Common Shares |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 5,333 | 30,219 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 5,333 | 4,677 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 1,777 | 24,886 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2023 | 1,777 | 10,010 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 10,321 | 10,321 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 4,677 | 11,787 | - | - | Restricted Stock Unit | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 27,400 | 27,400 | - | - | Stock Option (Right to Buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 47,231 | 497,045 | - | - | Share Option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 1,777 | 23,109 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2022 | 1,777 | 7,110 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 5,333 | 10,664 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 5,333 | 19,555 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 1,777 | 21,332 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 1,777 | 8,887 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 12,000 | 12,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 5,333 | 15,997 | - | - | Restricted Stock Unit | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 16.15 per share. | 30 Mar 2022 | 61,538 | 61,538 (0%) | 0% | 16.2 | 993,839 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 3.48 per share. | 30 Mar 2022 | 10,000 | 93,978 (0%) | 0% | 3.5 | 34,750 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 2.67 per share. | 30 Mar 2022 | 10,000 | 103,978 (0%) | 0% | 2.7 | 26,700 | Common Stock |
| 89bio Inc | Michael Hayden | Director | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 30 Mar 2022 | 6,250 | 83,978 (0%) | 0% | 3.6 | 22,625 | Common Stock |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 45,532 | 449,814 | - | - | Share option (right to buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 34,282 | 674,282 | - | - | Share option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 1,777 | 10,664 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 1,777 | 14,222 (0%) | 0% | 0 | Common Stock | |
| AbCellera Biologics Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.73 per share. | 13 Sep 2021 | 270,000 | 1,273,397 | - | 17.7 | 4,787,100 | Common Shares |
| AbCellera Biologics Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2021 | 270,000 | 270,000 | - | - | Share option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 5,333 | 14,219 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 5,333 | 10,667 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 1,778 | 12,441 | - | - | Restricted Stock Unit | |
| Ionis Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2021 | 1,778 | 12,445 (0%) | 0% | 0 | Common Stock | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 12,000 | 12,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ionis Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 5,333 | 19,552 | - | - | Restricted Stock Unit | |
| AbCellera Biologics Inc | Michael Hayden | Director | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 22 Jun 2021 | 100,000 | 1,003,397 | - | 25.5 | 2,550,000 | Common Shares |
| Xenon Pharma Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 18 May 2021 | 3,500 | 116,206 (0%) | 0% | 3.9 | 13,475 | Common Shares |
| Xenon Pharma Inc | Michael Hayden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 May 2021 | 3,500 | 0 | - | - | Stock Option (Right to Buy) | |
| 89bio Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2021 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) |